<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vavuranakis, Manolis</style></author><author><style face="normal" font="default" size="100%">Boudoulas, Konstantinos Dean</style></author><author><style face="normal" font="default" size="100%">Katsarou, Ourania</style></author><author><style face="normal" font="default" size="100%">Vrachatis, Dimitrios A</style></author><author><style face="normal" font="default" size="100%">Kalogeras, Konstantinos I</style></author><author><style face="normal" font="default" size="100%">Papaioannou, Theodore G</style></author><author><style face="normal" font="default" size="100%">Siasos, Gerasimos</style></author><author><style face="normal" font="default" size="100%">Oikonomou, Evangelos</style></author><author><style face="normal" font="default" size="100%">Lazaros, George</style></author><author><style face="normal" font="default" size="100%">Vavuranakis, Michael-Andreas</style></author><author><style face="normal" font="default" size="100%">Deftereos, Spyridon</style></author><author><style face="normal" font="default" size="100%">Tousoulis, Dimitrios</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Antiplatelet and Anticoagulation Therapy in Structural Heart Disease Interventions Beyond TAVI.</style></title><secondary-title><style face="normal" font="default" size="100%">Curr Pharm Des</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Curr Pharm Des</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Anticoagulants</style></keyword><keyword><style  face="normal" font="default" size="100%">Heart Diseases</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Platelet Aggregation Inhibitors</style></keyword><keyword><style  face="normal" font="default" size="100%">Transcatheter Aortic Valve Replacement</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2017</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2017</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">23</style></volume><pages><style face="normal" font="default" size="100%">1328-1333</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Transcatheter interventions for structural heart disease represent an emerging field in interventional cardiology. Undoubtedly, there is an absolute necessity for antiplatelet and/or anticoagulation treatment prior, during and post such interventions. However, currently administered regimens are mainly based in expert consensus recommendations. In the present review we aim to summarize data regarding anti platelet and/or anticoagulation treatment in the following transcatheter structural heart interventions: left atrial appendage closure, atrial septal defect closure, patent foramen oval closure, paravalvular leak closure.</style></abstract><issue><style face="normal" font="default" size="100%">9</style></issue><custom1><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/pubmed/28003014?dopt=Abstract</style></custom1></record></records></xml>